about
Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis.Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genesElevated mean neutrophil volume represents altered neutrophil composition and reflects damage after myocardial infarctionChemokines and atherosclerotic plaque progression: towards therapeutic targeting?Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors.Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice.Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice.An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation.Noncanonical NF-κB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction.Vaccination strategies in atherosclerosis.Heat-killed Staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages.Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis.Short Communication: The Neuropeptide Substance P Mediates Adventitial Mast Cell Activation and Induces Intraplaque Hemorrhage in Advanced AtherosclerosisSystemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differentlyPerivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E–Deficient MiceCXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient miceAtheroprotective properties of human Omentin-1 in experimental atherosclerosisIncreased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failureSmall molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failureExercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cellsPlatelet RNA modules point to coronary calcification in asymptomatic women with former preeclampsiaPotential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failureImmunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future PerspectivesRequirements for Proper Immunosuppressive Regimens to Limit Translational Failure of Cardiac Cell Therapy in Preclinical Large Animal Models
P50
Q33690049-10E75345-EFFC-4F2D-909E-CE299C49FDFCQ35085085-9BDE29E0-9AE0-4581-B56E-9A0B8FB0B9F1Q36162306-9B155F66-B058-4651-B3DD-58C3E64DE2D1Q36789673-A928F2EA-0010-4184-970E-F140ADF2789FQ37671303-6B98023A-1C01-4A8F-8EF0-9F34226919B9Q38175951-DFCA34EE-5D3C-4661-9E6A-A8D848FF8EA6Q39741685-69E41938-622D-4AB6-B1A0-3D5BD9572CDDQ44550417-8CA12DF1-6CE6-40FA-9F7A-261C69158E14Q44788268-7BDB0A4D-F08B-4188-88B4-7EDFCEF199CFQ45341784-0CEE24D2-6436-4CEB-8A36-B5FE52ECC170Q50172102-8EB9AE55-C765-40D0-B418-9EBC3E3428B9Q51668940-5F6B5BF7-55B6-417C-8C18-D0120AC3E5D7Q52883205-00CE2DCD-FEC7-4DCF-A271-BC3E0227692AQ52969715-91201326-AD16-42D0-AEFF-7723D754F6DCQ63258306-5F853630-5213-4FED-B26E-FB44870AB95DQ63258307-821D889D-8BCB-4720-945B-E77A19DDEAB8Q63258329-244F579B-83AD-4CD2-8D40-53F957F82A0EQ80120098-16941D77-EA66-40AC-9F07-62E6A7C9A5CBQ87402493-251331F3-65D6-4739-AF3C-CE56C48D8411Q90307990-9CC59388-B448-42EF-9933-668D34B3EFFCQ90908612-E51A9DD9-A36E-4F8D-BCBD-9D52C6A50679Q91174557-F6994B87-BCCE-47BC-8539-344B1449A41EQ91206361-57C577CD-333F-4521-B38C-539E87B4FE58Q92351043-F8DC794C-6C85-474B-9E87-0FA91DDA8EA7Q95661568-CA820EC4-8EB2-4694-9C18-A290E8D4DE29Q96019523-32FBDEDB-BDD4-4567-8FD3-B6DC98476A5F
P50
description
researcher
@en
wetenschapper
@nl
name
Saskia C A de Jager
@en
Saskia C A de Jager
@nl
type
label
Saskia C A de Jager
@en
Saskia C A de Jager
@nl
prefLabel
Saskia C A de Jager
@en
Saskia C A de Jager
@nl
P106
P31
P496
0000-0002-5233-0066